Analysts at CIBC started coverage on shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) in a note issued to investors on Friday. The brokerage set an “outperform” rating and a $19.00 price target on the biotechnology company’s stock. CIBC’s price objective indicates a potential upside of 74.79% from the company’s previous close.

Several other brokerages have also recently issued reports on MCRB. ValuEngine cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research cut shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Cantor Fitzgerald restated a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, August 30th. Finally, Canaccord Genuity set a $20.00 target price on shares of Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $18.00.

Seres Therapeutics (NASDAQ MCRB) traded up 1.0322% during trading on Friday, reaching $10.9822. The company had a trading volume of 69,036 shares. The firm’s market capitalization is $444.91 million. The firm’s 50 day moving average price is $14.20 and its 200 day moving average price is $14.20. Seres Therapeutics has a 12-month low of $8.85 and a 12-month high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.10). Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.00 million. During the same quarter in the prior year, the business posted ($0.70) EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year. Equities research analysts forecast that Seres Therapeutics will post ($2.55) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Seres Therapeutics, Inc. (MCRB) Research Coverage Started at CIBC” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/13/seres-therapeutics-inc-mcrb-research-coverage-started-at-cibc.html.

Several hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System raised its position in shares of Seres Therapeutics by 1.1% during the 2nd quarter. California State Teachers Retirement System now owns 36,280 shares of the biotechnology company’s stock valued at $410,000 after purchasing an additional 400 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Seres Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 2,410 shares during the period. State Street Corp raised its position in shares of Seres Therapeutics by 12.0% during the 2nd quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after purchasing an additional 34,393 shares during the period. Voya Investment Management LLC bought a new stake in shares of Seres Therapeutics during the 2nd quarter valued at $114,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Seres Therapeutics by 45.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 36,600 shares of the biotechnology company’s stock valued at $414,000 after purchasing an additional 11,488 shares during the period. Hedge funds and other institutional investors own 74.76% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.